Background. Long-term Epstein-Barr virus (EBV) monitoring for potentially life-threatening posttransplant lymphoproliferative disorder (PTLD) has identified asymptomatic patients who maintain high EBV loads over long periods.
(LMP1) and LMP2, as well as EBNA1, are expressed in latency type 2, as in Hodgkin disease. In latency type 3, highly immunogenic EBNA3 genes (EBNA3A, EBNA3B, and EBNA3C) are expressed, together with other EBV-latent antigens, as in posttransplant lymphoproliferative disorder (PTLD). The noncoding EBVencoded small RNAs (EBERs) and the BamHI A rightward transcripts (BARTs) are expressed in all latency types [1] [2] [3] . EBV-specific immune control is mediated by innate and adaptive immune responses. Disruption of the balance of antiviral immunity may lead to the development of EBV-associated disease [4] .
EBV-related PTLD is a significant cause of morbidity and mortality after solid-organ transplant in children. It has been reported that elevated levels of EBV DNA are a predictive factor for PTLD, and monitoring EBV loads in the peripheral blood of transplant recipients by polymerase chain reaction (PCR) can help identify patients at risk for developing PTLD before the onset of clinical signs [5] [6] [7] . Recently, serial viral load monitoring has identified a population of children who subsequently develop and maintain very high EBV loads in the absence of clinical symptoms [8] [9] [10] [11] [12] . This persistent presence of EBV DNA may increase the risk of late-onset PTLD. Previous reports have described the clinical courses among these patients after liver transplant, and a small number of them developed late-onset PTLD [10, 12] ; however, no pathophysiological analysis has been reported.
METHODS
Patients. Thirty-three pediatric liver transplant recipients who underwent living-donor liver transplant at Nagoya University School of Medicine from 1999 through 2007 were registered for this study. The primary diseases were biliary atresia ( ), fulminant hepatitis ( ), Alagille syndrome n p 25 n p 4 ( ), congenital absence of portal vein ( ), metastatic n p 1 n p 1 liver tumor ( ), and ornithine transcarbamylase deficiency n p 1 (
). We performed a prospective analysis of EBV load in n p 1 whole blood over the course of 6 months. Blood samples for the quantification of EBV DNA were obtained weekly until hospital discharge (median, 10 weeks after transplant; range, 6-37 weeks after transplant) and subsequently at each outpatient visit (monthly for 6 months) thereafter or until the EBV load resolved. Two patients were excluded from this study because they continued to be EBV seronegative throughout the study period. Chronic high EBV load was defined as the continuous presence of EBV loads 15000 copies/mL of whole blood for a minimum of 6 months after asymptomatic EBV infection or after complete resolution of symptomatic EBV infection; 11 patients met this criteria. Twenty pediatric liver transplant recipients who were not chronic high EBV load carriers were studied as control recipients. Blood samples for cell sorting, measurement of interleukin 10 (IL-10) concentration, tetramer staining, and real-time reverse-transcription PCR (RT-PCR) assay were obtained over the time of chronic high EBV load states. At the time of blood sampling, all patients were clinically asymptomatic. The results of these analyses were compared with those from 2 patients who developed EBV-related PTLD after a bone marrow transplant, 15 pediatric immunocompetent patients with acute-phase infectious mononucleosis (IM), and 25 healthy EBVseropositive adult carriers.
The standard immunosuppressive regimen consisted of tacrolimus and prednisolone, as reported elsewhere [13] . Target tacrolimus trough levels in plasma were as follows: 12-15 ng/ mL for the first 2 weeks after transplant, 10 ng/mL for the second through fourth weeks, 5-8 ng/mL for the first through sixth months, 5 ng/mL for the sixth through 12th months, and 2-3 ng/mL after the 12th month. When a liver transplant recipient who was positive for EBV developed clinical symptoms or the whole-blood EBV load increased to 15000 copies/mL, immunosuppression with tacrolimus was gradually decreased and kept at the minimum considered safe. Oral acyclovir (30-60 mg/kg/day) was administered until the EBV load decreased to !5000 copies/mL. No patient received antiviral prophylaxis in this study, and a preemptive approach was adopted to treat patients at risk for PTLD; indeed, no disease occurred.
Informed consent was obtained from all patients or their parents. This study was approved by the University of Nagoya Institutional Review Board.
Quantification of EBV DNA. Viral DNA was extracted from either 200 mL of whole blood or 10 6 peripheral blood mononuclear cells (PBMCs), using QIAamp DNA blood kits (Qiagen). A real-time quantitative PCR assay was performed, as described elsewhere [14, 15] . The minimum detection level was 2 copies per reaction, which is equivalent to ∼20 copies/ mg of DNA for PBMCs and 100 copies/mL for whole blood.
Determination of EBV-infected cells. To determine which cells harbored EBV, PBMCs were fractionated into CD3 + , CD19 + , and CD56 + cells by means of Dynabeads (Invitrogen). The fractionated cells were analyzed by real-time quantitative PCR. EBV-infected cell fractions were defined as having larger amounts of EBV DNA than of unfractionated PBMCs [14] .
Plasma concentration of IL-10. The plasma concentration of IL-10 was measured using enzyme-linked immunoassay kits (Quantikine HS Human IL-10 Immunoassay; R&D Systems). Normal plasma concentrations in healthy persons are 5 pg/mL or less. The samples for measurement of IL-10 were the same as those used for EBV load measurements. The mean times of blood sampling ‫ע‬ standard deviation (SD) were years after 1.6 ‫ע‬ 1.2 the onset of high EBV load status ( years after liver 3.0 ‫ע‬ 1.8 transplant) among chronic high EBV load carriers and 4.3 ‫ע‬ years after liver transplant among control recipients.
2.3
Tetramer staining. Fresh PBMCs from HLA-A2-positive and HLA-A24-positive persons were stained with a phycoerythrin-labeled major histocompatibility complex (MHC) class I tetrameric complex (Medical & Biological Laboratories) and a fluorescein isothiocyanate-labeled anti-CD8 monoclonal antibody (clone B9.11; Immunotech) and analyzed using a FACSCalibur flow cytometer (Becton Dickinson). For each analysis, CD8 + T cells were gated, and 30,000-150,000 events were acquired. The limit of detection was 0.01% of CD8 + T cells. The mean times of blood sampling ‫ע‬ SD were years after 3.0 ‫ע‬ 1.8 the onset of a high EBV load state ( years after liver 1.6 ‫ע‬ 1.2 transplant) among chronic high EBV load carriers and 4.3 ‫ע‬ years after liver transplant among control recipients. The 2.3 timing of sampling for tetramer staining was after the manipulation of immune suppression in all of the chronic high EBV load carriers. Five of 10 healthy control subjects and 6 of 11 chronic high EBV load carriers were analyzed at least twice during high EBV load periods to determine the stability of subpopulation frequencies.
RNA purification and real-time RT-PCR. RNA was extracted from PBMCs, using a QIAmp RNeasy Mini kit 6 2 ϫ 10 (Qiagen). Viral mRNA expression was quantified by 1-step multiplex real-time RT-PCR, using the Mx3000P real-time PCR system (Stratagene) as described elsewhere [16] . The stably expressed housekeeping gene b 2 -microgloblin (b2M) was used as an endogenous control and reference gene for relative quantification [17] . The detection limits for EBNA1, EBNA2, LMP1, LMP2, EBER1, BARTs, BamHI Z leftward reading frame 1 (BZLF1), and gp350/220 were 10 3 , 10 3 , 10 4 EBV-positive LCL cells of 10 6 EBV-negative BJAB cells, respectively. All chronic high EBV load carriers were analyzed at least twice over a 12-month period, and the results in all patients were similar.
Statistical analyses. Statistical analyses were conducted using StatView software (version 5.0; SAS Institute). The Fisher exact test or the Mann-Whitney U test was used for comparisons of 2 groups of patients. For comparisons of 13 groups, the Kruskal-Wallis test was used; if the result of the KruskalWallis test was significant, the Tukey-Kramer test was used as a post hoc test. For the negative samples, the default value, defined as the lowest level of expression for a particular gene, was used for the calculation. The default values for the undetected genes were 10 Ϫ8 . Differences with were deemed P ! .05 to be statistically significant.
RESULTS
Clinical characteristics and viral loads in peripheral blood from chronic high EBV load carriers. Characteristics of the 11 chronic high EBV load carriers are shown in Table 1 . In six patients, the onset of the high-load carrier state was preceded by EBV-related symptoms. These symptoms were transient and resolved after the reduction of immunosuppression in all patients. During the study period, the chronic high EBV load resolved without progression to PTLD in 7 (64%) of the 11 carriers, whereas the chronic high EBV load state continued with no symptoms in the other 4 carriers (36%). The median time to resolution in those whose high EBV load resolved was 23 months. Longitudinal analysis of EBV load in whole blood from each chronic high EBV load carrier is shown in Figure  1 . EBV DNA was not detected in most of the selected plasma samples from chronic high EBV load carriers throughout the chronic high EBV load state (data not shown). In some carriers, viral loads gradually decreased, whereas they continued to be elevated in others. For comparison, the median EBV load was copies/mL (range, -copies/mL) of 4 3 6 2.5 ϫ 10 1.9 ϫ 10 3.1 ϫ 10 whole blood for 15 patients with IM and copies/mL 5 4.0 ϫ 10 of whole blood for 2 patients who developed PTLD after a bone marrow transplant. EBV DNA was detected in 4 of 25 healthy control subjects (range, 0-copies/mL). 2 2.7 ϫ 10 Next, we compared clinical features between the chronic high EBV load carriers and control recipients ( Table 2) . Most of the chronic high EBV load carriers were seronegative for EBV before transplant, indicating that primary infection was a risk factor for the chronic high EBV load carrier state. Trough levels of tacrolimus were not significantly different, except 6 months after transplant, at which point the dose of tacrolimus was reduced because of the high EBV load.
Dominant EBV-infected cell compartments. Viral DNA was dominantly found only in a population of CD19 + cells of the peripheral blood from all chronic high EBV load carriers ( Figure 2) . Measurement of IL-10 concentration. Because several reports have demonstrated that levels of IL-10 might be predictive of the development of PTLD [18] , plasma concentrations of IL-10 were compared among chronic high EBV load carriers ( ), control recipients ( ), and patients with IM n p 11 n p 20 ( ). The mean levels of IL-10 in both chronic high EBV n p 14 patients and control recipients were not elevated (mean ‫ע‬ SD, and pg/mL, respectively), and no significant 2.1 ‫ע‬ 2.7 2.7 ‫ע‬ 5.7 difference was found between the 2 groups, although the levels in both groups were significantly lower than that in patients with IM (mean ‫ע‬ SD, pg/mL). 10.1 ‫ע‬ 6.5 Precursor frequency of EBV-specific CD8 + T cells in peripheral blood. HLA-A2 and HLA-A24 tetramers were used to analyze the precursor frequency of EBV-and cytomegalovirus (CMV)-specific CD8 + T cells in the 4 groups of subjects who had HLA-A2 or HLA-A24: chronic high EBV load carriers (A24, ; A2, ), control recipients (A24, ; A2, n p 8 n p 4 n p 13 ), healthy control subjects (A24, ), and patients n p 10 n p 10 with IM (A24, ). EBV-specific CD8 + T cells were detected n p 6 with 1 or more of the relevant tetramers in 9 of 10 chronic high EBV load carriers, in 18 of 19 control recipients, and in all subjects in the other groups. The frequency of EBV-and CMV-specific CD8 + T cells in the 4 groups are summarized in Figure 3A and 3B. The frequency of CD8 + T cells specific for lytic-cycle antigens (BamHI R leftward reading frame 1 [BRLF1] and BamHI M leftward reading frame 1 [BMLF1]) in patients with IM was significantly higher than in other groups. Regarding the 3 latent antigens (EBNA3A, EBNA3B, and LMP2), no statistical difference was found in the frequencies of EBV-specific CD8 + T cells among the groups, although the frequency of LMP2-specific CD8 + T cells were lower than those for the other epitopes in all groups. CMV pp65-specific CD8 + T cells were measured for comparison, and no difference was found in the frequencies among the groups.
Patterns of EBV-related gene expression in PBMCs. To investigate the levels and patterns of EBV gene expression, 6 latent and 2 lytic genes were quantified by multiplex real-time RT-PCR in all study groups. Representative quantitative results for chronic high EBV load carriers for each gene are shown in Figure 4A . EBER1 and BARTs were detected in all samples, and LMP2 was detected in 6 samples. EBER1 had the highest relative expression level, followed by BARTs and LMP2. The mean expression levels ‫ע‬ SD of EBER1, BARTs, and LMP2 were , , and , respectively. In contrast, more Figure 4D ). Additionally, EBER1 and BARTs with or without LMP2 were detected in only 2 of 20 control recipients, an expression pattern similar to that observed in the chronic high EBV load carriers (data not shown). With regard to healthy control subjects, EBER1 was detected in 2 of 23, and no other gene was detected in any of them.
DISCUSSION
Serial monitoring of EBV load for early diagnosis has become standard practice in the management of transplant recipients [5, [19] [20] [21] . This monitoring has led to the identification of a group of asymptomatic patients with chronic high EBV loads over long periods [10] [11] [12] . The incidence of chronic high EBV load, clinical features, and the risk of late-onset PTLD in liver transplantation have been reported by a few groups. D'Antiga et al [10] stated that 14 (41%) of 34 pediatric liver transplant recipients showed positive RT-PCR results for viral capsid antigen immunoglobulin M or early antigen immunoglobulin G lasting 16 months. Viral loads 1500 copies/10 5 PBMCs occurred in most of them. All 14 of these patients were seronegative for immunoglobulin G before transplant. Three patients developed late-onset PTLD. Green et al [12] reported that 36 (18%) of 196 children who had undergone liver transplant had 116,000 copies/mL of whole blood or 200 copies/10 5 PBMCs in at least 50% of samples over a minimum period of 6 months after EBV infection. Three-quarters of these children were negative for EBV before transplant. Only 1 patient developed PTLD. In the present study, 11 (35%) of 31 patients were found to be chronic high EBV carriers, and 10 of these 11 patients were seronegative for EBV before liver transplant, consistent with previous reports. No recipient with chronic high EBV loads developed late-onset PTLD. Because the majority of chronic high EBV load carriers were negative for EBV before transplant, primary EBV infection while receiving immunosuppressive drugs is key to understanding this chronic high EBV load carrier state.
Bingler et al [11] reported that 9 (45%) of 20 pediatric heart transplant recipients with chronic high EBV loads (defined as the presence of 116,000 copies/mL or 200 copies/10 5 PBMCs in at least 50% of samples over a minimum period of 6 months, developed late-onset PTLD. The incidence among heart recipients in this report was higher than those among liver recipients stated above. This difference may result from the aggressiveness of immunosuppression during the posttransplant period. The incidence of PTLD varies significantly between different types of organ transplantation [22, 23] . This variation is thought to be related to the degree and duration of immunosuppression and the number of EBV-positive donor lymphocytes in the graft. Additional studies are required to examine the association between the incidence of late-onset PTLD among those with chronic high EBV loads and the method of immunosuppression.
In the present study, a chronic high EBV load carrier state was defined as the continuous presence of EBV loads 15000 copies/mL of whole blood over a minimum period of 6 months ). n p 10 after asymptomatic infection or after complete resolution of symptomatic EBV disease. Previously, we reported that, in hematopoietic stem cell transplantation, 90.6% (3/32) of all asymptomatic patients had an EBV load !10 2.5 copies/mg of DNA (82.4% [14/17] of asymptomatic patients with a positive EBV load had !10 2.5 copies/mg of DNA), 83% (5/6) of the patients with clinical symptoms had between 10 2.5 and 10 4 copies/mg of DNA, and 100% (5/5) of patients who developed PTLD had 110 4 copies/mg of DNA [24] . Recently, we measured the EBV load in whole blood in order to monitor liver transplant patients, and our conversion factor from copies per microgram of DNA to copies per milliliter of whole blood was 10-20 (authors' unpublished data) . This conversion factor is close to that reported in another review [25] . Using this factor, 10 2.5 (equal to 316) copies/mg of DNA is similar to 3160-6320 copies/mL of whole blood, and we decided that 5000 copies/ mL of whole blood was the value expected to produce EBVrelated clinical symptoms but not PTLD in our system for quantifying the EBV load. CD8 + cytotoxic T cells are known to be important in controlling EBV-associated PTLD [4] . The combination of increased EBV load and the absence of EBV-specific CD8 + T cells can predict EBV lymphoproliferative disease [26] . Regarding the frequency of CD8 + T cells specific for 2 lytic antigens (BRLF1 and BMLF1) and 3 latent antigens (EBNA3A, EBNA3B, and LMP2), we found no significant difference between chronic high EBV load carriers and control recipients. Macedo et al [27] reported that the frequency of EBV-specific CD8 + T cells in "stable" (quiescent) transplant recipients was equal to or higher than that in healthy control subjects, which may agree with our results. In solid-organ transplant recipients, chronic administration of immunosuppressive drugs causes the impairment of cellular immune surveillance and allows EBV-infected B cells to proliferate. Smets et al [28] reported that recipients with high EBV loads showing low activity of specific CD8 + T were at high risk for PTLD, using an enzyme-linked immunospot assay in pediatric solid-organ transplant recipients. Such a functional impairment may be present and influence the chronic high EBV load state.
Analyzing the expression profile of EBV-related genes is useful in clarifying the pathogenesis of EBV-associated diseases [16] . In each chronic high EBV load carrier, EBER1 and BARTs were abundantly detected, and LMP2 was found in half of the carriers. The mean expression level of LMP2 was low, compared with those of EBER1 and BARTs. No transcript specific for latency type 3 was detected in chronic high EBV load carriers. This restricted pattern is latency type 0, which is found in EBVinfected memory B cells [8, 29, 30] , suggesting that the pattern of infected B cells in those with chronic high EBV loads may be the same as that in healthy EBV carriers. Qu et al [31] reported that peripheral blood lymphocytes in those with chronic high EBV loads after solid-organ transplant were divided into 2 types of infected cells: lymphocytes expressing LMP2 and carrying a low number of copies of EBV, and others coexpressing LMP1 and LMP2 and having a high number of copies of EBV. In the present study, expression of LMP1 was not observed in all chronic high EBV load carriers. Quantification in the blood sample may not have been sufficiently sensitive to detect a small population of infected cells expressing the LMP1 gene. Additionally, the expression pattern may vary with the time at which the blood sample is obtained. Transcripts specific for latency type 3 were detected in some samples from chronic high EBV load carriers obtained within 4 months after EBV infection (data not shown), and the pattern of EBV gene expression subsequently changed to latency type 0. Dynamic changes in the immune response, such as an increased precursor frequency of EBV-specific CD8 + T cells after reduced immune suppression, may influence expression patterns in chronic high EBV load carriers; however, this change was not evaluated in the present study.
After primary infection, EBV persists as a latent infection in memory B cells. Then, memory B cells occasionally differentiate into plasma cells that undergo lytic infection and produce new virus. Newly infected naive B cells become transformed but are controlled by CD8 + T cells specific for EBV. This cycle is necessary to maintain a latent infection in vivo [21, 32] . Thus, we suggest a novel mechanism for the maintenance of high viral loads in the blood of chronic high EBV load carriers. First, a large number of memory B cells latently infected with EBV survive after the primary or reactivated EBV infection occurring after transplant. Second, the latently infected memory B cells readily differentiate into plasma cells to produce the virus. Immunosuppression may influence these processes. Treatment with acyclovir or ganciclovir for a relatively prolonged period may modulate the chronic high EBV load state. However, our results did not provide mechanistic or therapeutic information.
